Normal Natural Killer Cell Activity in Hodgkin's Disease Patients in Remission

Overview

Journal Clin Exp Immunol

Publisher Oxford University Press

Specialty Allergy & Immunology

Date 1987 Sep 1

PMID 3665188

Citations 1

Authors

D Douer

N SHAKED

B Ramot

Affiliations

Soon will be listed here.

Abstract

Patients with untreated active Hodgkin's disease (HD) have a defect in cell-mediated immunity. After therapy many HD patients still have long lasting abnormalities in T cell number and function. We examined whether NK activity is also permanently impaired in HD patients in remission. The mean NK activity of peripheral blood lymphocytes from 42 patients who were disease-free for 6-150 months was not different from that of healthy controls. Augmentation of NK activity after treatment of the cells by interferon in vitro was equal for patients and controls. Normal NK activity in HD in remission was independent of disease stage, age, remission duration and mode of therapy. Measuring PHA-induced lymphocyte proliferation and NK activity simultaneously demonstrates that patients with impaired cell-mediated immunity do not have concomitant reduction of NK activity. We conclude that NK activity in HD in remission is independent of decreased T cell mediated immunity. In addition, NK is resistant to long term suppression by the chemotherapy and radiation protocols that are used in HD.

Citing Articles

Acquired Natural Killer Cell Dysfunction in the Tumor Microenvironment of Classic Hodgkin Lymphoma.

Chiu J, Ernst D, Keating A Front Immunol. 2018; 9:267.

PMID: 29491867 PMC: 5817071. DOI: 10.3389/fimmu.2018.00267.

References

Mantovani A, Luini W, Peri G, Vecchi A, Spreafico F . Effect of chemotherapeutic agents on natural cell-mediated cytotoxicity in mice. J Natl Cancer Inst. 1978; 61(5):1255-61. DOI: 10.1093/jnci/61.5.1255. View

Hercend T, Takvorian T, Nowill A, Tantravahi R, Moingeon P, Anderson K . Characterization of natural killer cells with antileukemia activity following allogeneic bone marrow transplantation. Blood. 1986; 67(3):722-8. View

Douer D, Sachs L . Differences in the formation of normal T lymphocyte colonies by peripheral blood cells from patients with chronic lymphocytic leukemia and Hodgkin's disease. Clin Exp Immunol. 1979; 38(3):514-22. PMC: 1537927. View

Karre K, Klein G, Kiessling R, Klein G, Roder J . Low natural in vivo resistance to syngeneic leukaemias in natural killer-deficient mice. Nature. 1980; 284(5757):624-6. DOI: 10.1038/284624a0. View

Fisher R, Devita Jr V, Bostick F, Vanhaelen C, Howser D, Hubbard S . Persistent immunologic abnormalities in long-term survivors of advanced Hodgkin's disease. Ann Intern Med. 1980; 92(5):595-9. DOI: 10.7326/0003-4819-92-5-595. View

Herberman R, Ortaldo J . Natural killer cells: their roles in defenses against disease. Science. 1981; 214(4516):24-30. DOI: 10.1126/science.7025208. View

Ruco L, Procopio A, Uccini S, Marcorelli E, Baroni C . Natural killer activity in spleens and lymph nodes from patients with Hodgkin's disease. Cancer Res. 1982; 42(5):2063-8. View

Pedersen-Bjergaard J, Larsen S . Incidence of acute nonlymphocytic leukemia, preleukemia, and acute myeloproliferative syndrome up to 10 years after treatment of Hodgkin's disease. N Engl J Med. 1982; 307(16):965-71. DOI: 10.1056/NEJM198210143071601. View

Tursz T, Dokhelar M, Lipinski M, AMIEL J . Low natural killer cell activity in patients with malignant lymphoma. Cancer. 1982; 50(11):2333-5. DOI: 10.1002/1097-0142(19821201)50:11<2333::aid-cncr2820501119>3.0.co;2-w. View

10.

Beran M, Hansson M, Kiessling R . Human natural killer cells can inhibit clonogenic growth of fresh leukemic cells. Blood. 1983; 61(3):596-9. View

11.

Hawrylowicz C, Rees R, Hancock B, POTTER C . Depressed spontaneous natural killing and interferon augmentation in patients with malignant lymphoma. Eur J Cancer Clin Oncol. 1982; 18(11):1081-8. DOI: 10.1016/0277-5379(82)90087-6. View

12.

Takagi S, Kitagawa S, Takeda A, Minato N, Takaku F, Miura Y . Natural killer-interferon system in patients with preleukaemic states. Br J Haematol. 1984; 58(1):71-81. DOI: 10.1111/j.1365-2141.1984.tb06060.x. View

13.

Young R, Corder M, Haynes H, DEVITA V . Delayed hypersensitivity in Hodgkin's disease. A study of 103 untreated patients. Am J Med. 1972; 52(1):63-72. DOI: 10.1016/0002-9343(72)90008-3. View

14.

Corder M, Young R, Brown R, DEVITA V . Phytohemagglutinin-induced lymphocyte transformation: the relationship to prognosis of Hodgkin's disease. Blood. 1972; 39(5):595-601. View

15.

Eltringham J, Kaplan H . Impaired delayed-hypersensitivity responses in 154 patients with untreated Hodgkin's disease. Natl Cancer Inst Monogr. 1973; 36:107-15. View

16.

Levy R, Kaplan H . Impaired lymphocyte function in untreated Hodgkin's disease. N Engl J Med. 1974; 290(4):181-6. DOI: 10.1056/NEJM197401242900402. View

17.

Bobrove A, Fuks Z, Strober S, Kaplan H . Quantitation of T and B lymphocytes and cellular immune function in Hodgkin's disease. Cancer. 1975; 36(1):169-79. DOI: 10.1002/1097-0142(197507)36:1<169::aid-cncr2820360115>3.0.co;2-z. View

18.

Ramot B, Biniaminov M, Shoham C, Rosenthal E . Effect of levamisole on E-rosette-forming cells in vivo and in vitro in Hodgkin's disease. N Engl J Med. 1976; 294(15):809-11. DOI: 10.1056/NEJM197604082941504. View

19.

Oehler J, Herberman R . Natural cell-mediated cytotoxicity in rats. III. Effects of immunopharmacologic treatments on natural reactivity and on reactivity augmented by polyinosinic-polycytidylic acid. Int J Cancer. 1978; 21(2):221-9. DOI: 10.1002/ijc.2910210214. View

20.

Levy S, Tempe J, Aleksijevic A, Giron C, Oberling F, Mayer S . Depressed NK cell activity of peripheral blood mononuclear cells in untreated hodgkin's disease: enhancing effect of interferon in vitro. Scand J Haematol. 1984; 33(4):386-90. DOI: 10.1111/j.1600-0609.1984.tb00712.x. View